KENNETH ALAN FREEDBERG

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India
    Kartik K Venkatesh
    Division of Infectious Disease, Department of Medicine, Alpert Medical School, Brown University Miriam Hospital, Providence, Rhode Island, United States of America
    PLoS ONE 8:e64604. 2013
  2. pmc Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability
    April D Kimmel
    Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Cost Eff Resour Alloc 10:12. 2012
  3. pmc Improving HIV outcomes in resource-limited countries: the importance of quality indicators
    Aima A Ahonkhai
    Divisions of Infectious Disease, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
    BMC Health Serv Res 12:427. 2012
  4. pmc Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, and Center for AIDS Research, Harvard Medical School, Boston, MA, USA
    BMC Med 9:59. 2011
  5. pmc Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
    Jennifer Chu
    Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, USA
    AIDS Res Ther 8:14. 2011
  6. pmc Food assistance is associated with improved body mass index, food security and attendance at clinic in an HIV program in central Haiti: a prospective observational cohort study
    Louise C Ivers
    Division of Global Health Equity, Brigham and Women s Hospital, Boston, Massachusetts, USA
    AIDS Res Ther 7:33. 2010
  7. ncbi request reprint The cost effectiveness of combination antiretroviral therapy for HIV disease
    K A Freedberg
    Division of General Internal Medicine and the Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 344:824-31. 2001
  8. pmc Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Disease and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA, USA
    AIDS 21:S117-28. 2007
  9. ncbi request reprint Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Diseases and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 43:S113-8. 2006
  10. ncbi request reprint Improving participation in HIV clinical trials: impact of a brief intervention
    K A Freedberg
    Division of General Internal Medicine and Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    HIV Clin Trials 2:205-12. 2001

Research Grants

  1. PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)
    Kenneth Freedberg; Fiscal Year: 2007
  2. Optimizing HIV Care in Less Developed Countries
    Kenneth Freedberg; Fiscal Year: 2009
  3. Optimizing HIV Care in Less Developed Countries
    KENNETH ALAN FREEDBERG; Fiscal Year: 2010
  4. Optimizing HIV Care in Less Developed Countries
    Kenneth Freedberg; Fiscal Year: 2009
  5. Optimizing HIV Care in Less Developed Countries
    Kenneth Freedberg; Fiscal Year: 2007
  6. Optimal Strategies for Management of HIV Disease
    Kenneth Freedberg; Fiscal Year: 2007
  7. COST EFFECTIVENESS OF PREVENTING HIV COMPLICATIONS
    Kenneth Freedberg; Fiscal Year: 2001
  8. Cost-effectiveness of preventing HIV complications
    Kenneth Freedberg; Fiscal Year: 2005
  9. Cost-effectiveness of preventing HIV complications
    Kenneth Freedberg; Fiscal Year: 2007
  10. Optimizing HIV Care in Less Developed Countries
    KENNETH ALAN FREEDBERG; Fiscal Year: 2010

Collaborators

Detail Information

Publications70

  1. pmc Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India
    Kartik K Venkatesh
    Division of Infectious Disease, Department of Medicine, Alpert Medical School, Brown University Miriam Hospital, Providence, Rhode Island, United States of America
    PLoS ONE 8:e64604. 2013
    ..Despite expanding access to antiretroviral therapy (ART), most of the estimated 2.3 to 2.5 million HIV-infected individuals in India remain undiagnosed. The questions of whom to test for HIV and at what frequency remain unclear...
  2. pmc Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability
    April D Kimmel
    Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Cost Eff Resour Alloc 10:12. 2012
    ..abstract:..
  3. pmc Improving HIV outcomes in resource-limited countries: the importance of quality indicators
    Aima A Ahonkhai
    Divisions of Infectious Disease, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
    BMC Health Serv Res 12:427. 2012
    ..Resource-limited countries increasingly depend on quality indicators to improve outcomes within HIV treatment programs, but indicators of program performance suitable for use at the local program level remain underdeveloped...
  4. pmc Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, and Center for AIDS Research, Harvard Medical School, Boston, MA, USA
    BMC Med 9:59. 2011
    ....
  5. pmc Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
    Jennifer Chu
    Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, USA
    AIDS Res Ther 8:14. 2011
    ..abstract:..
  6. pmc Food assistance is associated with improved body mass index, food security and attendance at clinic in an HIV program in central Haiti: a prospective observational cohort study
    Louise C Ivers
    Division of Global Health Equity, Brigham and Women s Hospital, Boston, Massachusetts, USA
    AIDS Res Ther 7:33. 2010
    ..We evaluated the impact of food assistance on patient outcomes in a comprehensive HIV program in central Haiti in a prospective observational cohort study...
  7. ncbi request reprint The cost effectiveness of combination antiretroviral therapy for HIV disease
    K A Freedberg
    Division of General Internal Medicine and the Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 344:824-31. 2001
    ..We estimated the clinical benefits and cost effectiveness of three-drug antiretroviral regimens...
  8. pmc Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Disease and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA, USA
    AIDS 21:S117-28. 2007
    ..India has more than 5.7 million people infected with human immunodeficiency virus (HIV). In 2004, the Indian government began providing antiretroviral therapy (ART), and there are now an estimated 56 500 people receiving ART...
  9. ncbi request reprint Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Diseases and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 43:S113-8. 2006
    ..Adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds...
  10. ncbi request reprint Improving participation in HIV clinical trials: impact of a brief intervention
    K A Freedberg
    Division of General Internal Medicine and Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    HIV Clin Trials 2:205-12. 2001
    ....
  11. ncbi request reprint The private side of the professional man
    Kenneth A Freedberg
    Program in HIV Epidemiology and Outcomes Research, Massachusetts General Hospital, Medical Practices Evaluation Center, Boston, Massachusetts 02114, USA
    J Invest Dermatol 126:533-5. 2006
  12. pmc When to start antiretroviral therapy in resource-limited settings
    Rochelle P Walensky
    Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
    Ann Intern Med 151:157-66. 2009
    ..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
  13. ncbi request reprint Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  14. ncbi request reprint Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults
    Bruce R Schackman
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Arch Intern Med 162:2478-86. 2002
    ....
  15. ncbi request reprint Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS
    Bruce R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Med Decis Making 22:27-38. 2002
    ....
  16. ncbi request reprint Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview
    Elena Losina
    Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
    Clin Infect Dis 38:1613-22. 2004
    ..The best response was seen in NNRTI-naive patients receiving NNRTI- and boosted PI-containing regimens. New approaches are needed to achieve better suppression in pretreated HIV-infected patients...
  17. ncbi request reprint Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines
    Sue J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115 5924, USA
    Arch Intern Med 162:921-8. 2002
    ....
  18. ncbi request reprint Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
    Sue J Goldie
    Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Am J Med 115:632-41. 2003
    ..To explore the cost-effectiveness of interventions to improve adherence to combination antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection...
  19. pmc Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal
    Elena Losina
    Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS Med 6:e1000173. 2009
    ..Our objective was to project the clinical impact and cost-effectiveness of interventions to prevent LTFU from HIV care in West Africa...
  20. ncbi request reprint The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality
    George R Seage
    Department of Epidemiology and Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Acquir Immune Defic Syndr 30:421-8. 2002
    ....
  21. ncbi request reprint Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection
    George J Hanna
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 188:986-91. 2003
    ..Serological results indicated infection for >/=6 months. Drug-selected mutations or non-B subtypes were detected in a substantial portion of antiretroviral-naive adults who had been infected for at least 6 months...
  22. ncbi request reprint Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center
    Jonathan M Pincus
    Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Clin Infect Dis 37:1699-704. 2003
    ..Given the importance of this diagnosis, testing for acute HIV infection using RNA and antibody assays should be offered to all patients in similar settings with viral symptoms and any risk factors for HIV infection...
  23. pmc The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
    Florencia Pereyra
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology MIT and Harvard, Boston, MA, USA
    Science 330:1551-7. 2010
    ..These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection...
  24. pmc Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy
    Elena Losina
    Divisions of General Medicine, Department of Medicine, MA 02114, USA
    Clin Infect Dis 49:1570-8. 2009
    ....
  25. pmc HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies
    Michael D April
    Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 51:310-6. 2009
    ..Revised World Health Organization recommendations seek to increase HIV testing. We assessed the need for expanded testing in South Africa by examining current testing and treatment trends among a high prevalence population...
  26. pmc Loss to care and death before antiretroviral therapy in Durban, South Africa
    Ingrid V Bassett
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 51:135-9. 2009
    ..To examine the loss to care and mortality rates before starting antiretroviral therapy (ART) among ART eligible HIV-infected patients in Durban, South Africa. Design: Retrospective cohort study...
  27. pmc Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA
    HIV Clin Trials 10:13-24. 2009
    ..We describe the frequency with which these posttrial services are described in the protocols and informed consent forms (ICFs) of antiretroviral drug (ARV) trials...
  28. pmc Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa
    Bisola O Ojikutu
    Harvard Center for AIDS Research CFAR and Division of AIDS, Harvard Medical School, and Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA
    S Afr Med J 98:204-8. 2008
    ..To identify predictors of mortality in patients initiating antiretroviral therapy (ART) in Durban, South Africa...
  29. pmc Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity
    Andrea L Ciaranello
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    AIDS 22:2359-69. 2008
    ..We sought to identify the currently recommended regimen to prevent mother-to-child transmission that optimally balances risks of pediatric HIV infection and neurologic mitochondrial toxicity...
  30. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  31. pmc Improving outcomes in state AIDS drug assistance programs
    Benjamin P Linas
    Divisions of General Medicine, Massachusetts General Hospital, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 51:513-21. 2009
    ..State AIDS Drug Assistance Programs (ADAPs) provide antiretroviral medications to patients with no access to medications. Resource constraints limit the ability of many ADAPs to meet demand for services...
  32. pmc Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should
    Ingrid V Bassett
    Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA
    AIDS 24:S37-44. 2010
    ..To evaluate rates of antiretroviral therapy (ART) initiation within 12 months of a new HIV diagnosis in Durban, South Africa...
  33. pmc First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA
    AIDS 25:479-92. 2011
    ..nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine...
  34. pmc Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS Med 7:e1000382. 2010
    ..This paper considers what to do first in resource-limited settings where immediate implementation of all of the WHO recommendations is not feasible...
  35. pmc Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    HIV Clin Trials 11:248-59. 2010
    ..We project the life expectancies, costs, and incremental cost-effectiveness ratios (ICERs) of these strategies...
  36. pmc The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 56:26-35. 2011
    ..Although 900,000 HIV-infected South Africans receive antiretroviral therapy, the majority of South Africans with HIV remain undiagnosed...
  37. pmc Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa
    Ingrid V Bassett
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 51:823-9. 2010
    ..Our objective was to assess the yield and cost of a more intensive tuberculosis screening in HIV-infected patients starting antiretroviral therapy (ART) in Durban, South Africa...
  38. pmc Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 51:392-400. 2010
    ..We forecast outcomes of this approach if implemented in Washington DC...
  39. pmc Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature
    Rochelle P Walensky
    Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 51:85-92. 2010
    ....
  40. pmc The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa
    Elena Losina
    Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 5:e9538. 2010
    ..Our objective was to determine PTLC in newly identified HIV-infected individuals in South Africa...
  41. pmc Predicting virologic failure in an HIV clinic
    Gregory K Robbins
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 50:779-86. 2010
    ..We sought to use data captured in the electronic health record (EHR) to develop and validate a prediction rule for virologic failure among patients being treated for infection with human immunodeficiency virus (HIV)...
  42. pmc Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India
    Melissa A Bender
    Divisions of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 50:416-25. 2010
    ..We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine...
  43. pmc Cost-effectiveness of HIV testing and treatment in the United States
    Rochelle P Walensky
    Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 45:S248-54. 2007
    ..This article reviews the methods and results of cost-effectiveness studies in the United States and articulates why routine, voluntary HIV testing is not only of crucial public health importance but also economically justified...
  44. ncbi request reprint Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Med Decis Making 25:321-9. 2005
    ..Using the example of HIV testing, the authors explore the optimal targeting of funds within this pathway...
  45. ncbi request reprint Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease
    Paul E Sax
    Division of Infectious Disease and the Partners AIDS Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 39:69-77. 2005
    ..Because of the high cost of ENF compared with other antiretroviral agents, our objectives were to determine the potential long-term clinical impact and cost-effectiveness of ENF in these patients...
  46. ncbi request reprint Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients
    April D Kimmel
    Division of General Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Antivir Ther 10:41-52. 2005
    ..Guidelines regarding the frequency of CD4 cell count and HIV RNA monitoring in HIV-infected patients vary, with recommended strategies ranging from every 2 to every 6 months...
  47. ncbi request reprint Routine human immunodeficiency virus testing: an economic evaluation of current guidelines
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Med 118:292-300. 2005
    ..Our objective was to evaluate the clinical effect and cost-effectiveness of current guidelines and of alternate HIV prevalence thresholds...
  48. pmc Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts
    Rochelle P Walensky
    Division of General Medicine, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
    Am J Public Health 95:71-3. 2005
    ..Urgent care center-based routine HIV counseling, testing, and referral programs are feasible, can have high positive diagnosis yields, and should be the standard of care in high HIV prevalence areas...
  49. ncbi request reprint A therapeutic HIV vaccine: how good is good enough?
    Rochelle P Walensky
    Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, MA 02114, USA
    Vaccine 22:4044-53. 2004
    ..91 months (cost-effectiveness ratio US$ 45,500/QALY). Even modestly effective therapeutic HIV vaccines may produce small but meaningful increases in life expectancy and compare favorably to alternative uses of scarce HIV care resources...
  50. ncbi request reprint Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV
    Ingrid V Bassett
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Infect Dis 39:395-401. 2004
    ....
  51. ncbi request reprint Alcohol consumption and HIV disease progression: are they related?
    Jeffrey H Samet
    Clinical Addiction Research and Education CARE Unit, Section of General Internal Medicine, Boston Medical Center, 91 East Concord Street, Suite 200, Boston, MA 02118, USA
    Alcohol Clin Exp Res 27:862-7. 2003
    ..The relationship between alcohol consumption and HIV disease progression has received limited attention in the era of highly active antiretroviral therapy (HAART)...
  52. ncbi request reprint Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa
    Charles B Holmes
    Division of Infectious Disease, Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 36:652-62. 2003
    ..Policies regarding the type and timing of opportunistic infection prophylaxis may be region specific and urgently require further study...
  53. ncbi request reprint Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy
    Rochelle P Walensky
    Division of Infectious Disease and the Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Acquir Immune Defic Syndr 31:27-37. 2002
    ..These results can assist decision makers and those planning clinical trials in defining evidence-based performance measures for primary HIV infection treatment and future trials...
  54. ncbi request reprint AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States
    Rochelle P Walensky
    Division of Infectious Disease and the Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Infect Dis 35:606-10. 2002
    ..Cost-effectiveness analysis would offer a more informed basis for distribution of ADAP resources in an efficient and equitable manner, leading to a standardized national structure...
  55. ncbi request reprint Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Infect Dis 41:1316-23. 2005
    ..Our objective was to determine the clinical impact and cost-effectiveness of genotype resistance testing for treatment-naive patients with chronic HIV infection...
  56. pmc Assessing the impact of federal HIV prevention spending on HIV testing and awareness
    Benjamin P Linas
    Massachusetts General Hospital, 50 Staniford St, Ninth Floor, Boston, MA 02114, USA
    Am J Public Health 96:1038-43. 2006
    ..The United States allocates more than $900 million annually for the prevention of HIV infection. We assessed the impact of this funding on HIV testing and knowledge...
  57. ncbi request reprint Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost
    Charles B Holmes
    Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 42:1772-80. 2006
    ..Our objectives were to project the tradeoffs regarding life expectancy, cost, and cost-effectiveness of these ART regimens for NVP-exposed, HIV-infected women in South Africa...
  58. pmc The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean
    Lindsey L Wolf
    Division of General Medicine and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 46:463-71. 2007
    ..Antiretroviral therapy (ART) recently became available in the Organization of Eastern Caribbean States (OECS). Survival benefits and budgetary implications associated with universal access to ART have not been examined in the Caribbean...
  59. pmc HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993--2005
    Elena Losina
    Division of General Medicine and Infectious Diseases, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, Massachusetts 02114, USA
    Int J Infect Dis 12:132-8. 2008
    ..Using Jamaican national surveillance data, we estimated overall, AIDS-free, and AIDS survival, identified factors influencing HIV-related mortality, and examined factors associated with late HIV/AIDS identification...
  60. pmc The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire
    Elena Losina
    Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA, USA
    Antivir Ther 12:543-51. 2007
    ..Studies in developed countries have shown highly active antiretroviral therapy (HAART) decreases incidence of severe opportunistic diseases (ODs) in HIV-infected patients beyond that which is expected from changes in CD4+ T-cell count...
  61. pmc Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department
    Ingrid V Bassett
    Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 46:181-6. 2007
    ..To evaluate the yield of a routine voluntary HIV testing program compared with traditional provider-referred voluntary counseling and testing (VCT) in a hospital-affiliated outpatient department (OPD) in Durban, South Africa...
  62. pmc HIV drug resistance surveillance for prioritizing treatment in resource-limited settings
    Rochelle P Walensky
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    AIDS 21:973-82. 2007
    ..Sentinel testing programs for HIV drug resistance in resource-limited settings can inform policy on antiretroviral therapy (ART) and drug sequencing...
  63. pmc Visual screening for malignant melanoma: a cost-effectiveness analysis
    Elena Losina
    Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
    Arch Dermatol 143:21-8. 2007
    ..To evaluate the cost-effectiveness of various melanoma screening strategies proposed in the United States...
  64. pmc Predictors of antiretroviral treatment failure in an urban HIV clinic
    Gregory K Robbins
    Division of Infectious Diseases, Massachusetts General Hospital, Harvard Center for AIDS Research CFAR, and Harvard Medical School, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 44:30-7. 2007
    ..Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations...
  65. ncbi request reprint Optimizing resource allocation in United States AIDS drug assistance programs
    Benjamin P Linas
    Division of General Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Infect Dis 43:1357-64. 2006
    ..We hypothesized that CD4 cell count-based ADAP eligibility would improve ADAP outcomes, allowing them to serve more-diverse patient populations and to prioritize persons who are at greatest risk of HIV-related mortality...
  66. pmc Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries
    April D Kimmel
    Division of General Medicine, Massachusetts General Hospital, Boston 02114, USA
    Bull World Health Organ 84:581-8. 2006
    ..We recommend classifying information into clinically relevant categories, using a consistent definition of disease across studies and providing measures of both association and accuracy...
  67. ncbi request reprint CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment
    Charles B Holmes
    Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 42:464-9. 2006
    ..To determine the rate of CD4 decline and the incidence of opportunistic infections (OIs) among antiretroviral therapy-naive South African HIV-infected patients and inform timing of OI prophylaxis...
  68. ncbi request reprint The survival benefits of AIDS treatment in the United States
    Rochelle P Walensky
    Division of Infectious Disease and General Medicine, Massachusetts General Hospital, Boston 02114, USA
    J Infect Dis 194:11-9. 2006
    ..As widespread adoption of potent combination antiretroviral therapy (ART) reaches its tenth year, our objective was to quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United States...
  69. ncbi request reprint Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing
    Rochelle P Walensky
    Division of Infectious Disease and Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, 50 Staniford St, Ninth Floor, Boston, MA 02114, USA
    Arch Intern Med 162:887-92. 2002
    ....
  70. ncbi request reprint Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems
    Jeffrey H Samet
    Clinical Addiction Research and Education CARE Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Alcohol Clin Exp Res 28:572-7. 2004
    ..We examined the relative importance of varying levels of alcohol consumption on adherence in HIV-infected patients with a history of alcohol problems...

Research Grants24

  1. PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)
    Kenneth Freedberg; Fiscal Year: 2007
    ..The proposed continuation will allow the PACRT to help train the next generation of highly successful investigators to address the complex and evolving issues arising today in HIV clinical research. ..
  2. Optimizing HIV Care in Less Developed Countries
    Kenneth Freedberg; Fiscal Year: 2009
    ..The flexibility of our program allows our team to investigate problems from several angles, providing insight into scenarios that may not be feasible to test in real-life settings through large-scale clinical trials. ..
  3. Optimizing HIV Care in Less Developed Countries
    KENNETH ALAN FREEDBERG; Fiscal Year: 2010
    ..The flexibility of our program allows our team to investigate problems from several angles, providing insight into scenarios that may not be feasible to test in real-life settings through large-scale clinical trials. ..
  4. Optimizing HIV Care in Less Developed Countries
    Kenneth Freedberg; Fiscal Year: 2009
    ..The flexibility of our program allows our team to investigate problems from several angles, providing insight into scenarios that may not be feasible to test in real-life settings through large-scale clinical trials. ..
  5. Optimizing HIV Care in Less Developed Countries
    Kenneth Freedberg; Fiscal Year: 2007
    ....
  6. Optimal Strategies for Management of HIV Disease
    Kenneth Freedberg; Fiscal Year: 2007
    ..Freedberg will create a multiplicative effect in increasing research capability in this important area of HIV-related patient-oriented investigation. ..
  7. COST EFFECTIVENESS OF PREVENTING HIV COMPLICATIONS
    Kenneth Freedberg; Fiscal Year: 2001
    ..The ultimate objective is to provide timely information which will be useful to clinicians and policy makers in developing rational approaches for the management of HIV. ..
  8. Cost-effectiveness of preventing HIV complications
    Kenneth Freedberg; Fiscal Year: 2005
    ..Our aim, in the present proposal, is to exert an equally important impact in the years to come. ..
  9. Cost-effectiveness of preventing HIV complications
    Kenneth Freedberg; Fiscal Year: 2007
    ..In this proposal, our objective is to continue to exert a major impact on HIV care in the United States over the next 4 years. ..
  10. Optimizing HIV Care in Less Developed Countries
    KENNETH ALAN FREEDBERG; Fiscal Year: 2010
    ..The flexibility of our program allows our team to investigate problems from several angles, providing insight into scenarios that may not be feasible to test in real-life settings through large-scale clinical trials. ..